Cart
sales@molnova.com
Lipoteichoic acid
CAS No. 56411-57-5
Lipoteichoic acid( —— )
Catalog No. M35221 CAS No. 56411-57-5
Lipoteichoic acid, a polymer of Staphylococcus aureus cell wall, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 298 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLipoteichoic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionLipoteichoic acid, a polymer of Staphylococcus aureus cell wall, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.
-
DescriptionLipoteichoic acid, a cell wall component of Staphylococcus aureus, activates the complement system via C3 induction and CD55 inhibition.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number56411-57-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (Ultrasonic ) H2O : 10 mg/mL (Ultrasonic)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bong Jun Jung, et al. Lipoteichoic Acid from Staphylococcus aureus Activates the Complement System via C3 Induction and CD55 Inhibition. Microorganisms. 2021 May 24;9(6):1135.?
molnova catalog
related products
-
Factor D inhibitor 7
Factor D inhibitor 7 is a potent and selective, orally bioavailable inhibitor of Factor D with IC50 of 50 nM.
-
PMX53
PMX53 (Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)) is a potent C5a receptor (CD88) antagonist with IC50 of 20 nM.
-
Vesencumab
Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.
